Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas.

NCT02333565 is registered in ClinicalTrials.gov with Assistance Publique Hopitaux De Marseille as lead sponsor.

NCT NCT02333565
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02333565 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas.
Lead sponsor
Assistance Publique Hopitaux De Marseille
Phase
Phase 2
Overall status
Completed
Start date
January 22, 2015
Completion date
May 24, 2023
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent meningiomas, resistant meningiomas